Teva Pharmaceutical Industries (TEVA) Cash & Equivalents (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Cash & Equivalents across 18 years of filings, most recently posting $3.7 billion for Q1 2026.

• Quarterly Cash & Equivalents rose 120.45% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (up 120.45% YoY) and the FY2025 annual result came in at $3.6 billion, up 7.76% from the prior year.
• Cash & Equivalents improved to $3.7 billion in Q1 2026, from $3.6 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $3.7 billion in Q1 2026 and troughed at $1.7 billion in Q1 2025.
• A 5-year average of $2.6 billion and a median of $2.3 billion in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 43.26% — and 2026, when it jumped 120.45%.
• Tracing TEVA's Cash & Equivalents over 5 years: stood at $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then climbed by 2.29% to $3.3 billion in 2024, then advanced by 7.76% to $3.6 billion in 2025, then gained by 5.2% to $3.7 billion in 2026.
• Business Quant data shows TEVA's Cash & Equivalents at $3.7 billion in Q1 2026, $3.6 billion in Q4 2025, and $2.2 billion in Q3 2025.